AGENT - AGENT

Description:

The goal of the Angiogenic Gene Therapy (AGENT) trial was to assess the safety and efficacy of angiogenesis therapy with a human fibroblast growth factor gene among patients with chronic stable angina, and to select safe and effective doses of the gene for future studies.